EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor

Okuyucu E. E., Guven O., Duman T., GÖRÜR S., Melek I. M., Akcin S., ...Daha Fazla

Neurological Research, cilt.31, sa.3, ss.313-315, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 3
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1179/174313209x382548
  • Dergi Adı: Neurological Research
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.313-315
  • Anahtar Kelimeler: Electroencephalography, Phosphodiesterase type 5 inhibitor, Tadalafil
  • Hatay Mustafa Kemal Üniversitesi Adresli: Evet

Özet

Objective: Tadalafil is a selective phosphodiesterase type 5 (PDE-5) inhibitor approved for the treatment of erectile dysfunction. Less is known about the electroencephalography (EEG) effects of PDE-5 inhibitors, and the present study, therefore, examined the risk of EEG abnormalities associated with tadalafil. Method: EEG recordings from 35 erectile dysfunction patients taking tadalafil (20 mg) were graded for severity of EEG abnormalities (at admission, 2 and 48 hours after tadalafil administration). Results: At admission, there were no EEG abnormalities. At second EEG, abnormalities occurred in 12 (34.3%) of the 35 patients. Eight (22.9%) patients had mild and four (11.4%) patients had moderate EEG abnormalities. At third EEG, one (2.9%) patient had mild and one (2.9%) patient had moderate EEG abnormalities. Conclusion: PDE-5 inhibitors may produce EEG abnormalities. Although the exact role of PDE in altering susceptibility to seizure remains unclear, epileptic seizures may occur during treatment with PDE inhibitors. © 2009 W. S. Maney & Son Ltd.